Articles that tag IPHA but are mainly about other companies.
Presented as the closest mechanistic comparison with an NK cell engager platform that achieved Phase 2 advancement and FDA Fast Track designation. However, the article notes strategic resets and the return of program rights from Sanofi, indicating both promise and turbulence in the field.
Advancing Lacutamab (Phase II KIR3DL2 receptor antagonist) with FDA clearance to proceed with confirmatory Phase III protocol, demonstrating regulatory progress
Lacutamab (IPH4102), a first-in-class KIR3DL2-targeting antibody, is under evaluation in Phase II trials for PTCL with data expected by end of 2026, representing advancement in novel treatment approaches.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
